Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 443-452

  De Castro, Ana ^a,b   Jones, Hendreé E ^c   Johnson, Rolley E ^d   Gray, Teresa R ^a   Shakleya, Diaa M ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c RTI INTERNATIONAL   (United States)

^d RECKITT BENCKISER   (United Kingdom)

Author keywords

Cocaine; In utero drug exposure; Methadone; Opiates; Umbilical cord

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; COCAINE; ILLICIT DRUG; METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG ABUSE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG INFORMATION; FEMALE; HUMAN; MECONIUM; METABOLITE; NEWBORN; OUTCOME ASSESSMENT; PLACENTA; PREGNANCY; PRIORITY JOURNAL; SCORING SYSTEM; UMBILICAL CORD; URINALYSIS; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MECONIUM; METHADONE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PYRROLIDINES; UMBILICAL CORD;

EID: 80051789107     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31822724f0     Document Type: Article

References (52)

1. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings; 2009.
2. Huestis MA, Choo RE. Drug abuse's smallest victims: in utero drug exposure. Forensic Sci Int. 2002;128:20-30.
3. Behnke M, Eyler FD. The consequences of prenatal substance use for the developing fetus, newborn, and young child. Int J Addict. 1993;28: 1341-1391. (Pubitemid 23350948)
4. Miles DR, Lanni S, Jansson L, et al. Smoking and illicit drug use during pregnancy: impact on neonatal outcome. J Reprod Med. 2006;51: 567-572. (Pubitemid 44099998)
5. Richardson GA, Hamel SC, Goldschmidt L, et al. The effects of prenatal cocaine use on neonatal neurobehavioral status. Neurotoxicol Teratol. 1996;18:519-528. (Pubitemid 26346097)
6. van Baar AL, Soepatmi S, Gunning WB, et al. Development after prenatal exposure to cocaine, heroin and methadone. Acta Paediatr Suppl. 1994; 404:40-46. (Pubitemid 24349136)
7. Velez ML, Jansson LM, Schroeder J, et al. Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res. 2009;66:704-709.
8. Jones HE, O'Grady KE, Malfi D, et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372-386.
9. Finnegan LP. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs. 1991;23:191-201.
10. Winklbaur B, Kopf N, Ebner N, et al. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 2008;103:1429-1440.
11. Bakstad B, Sarfi M,Welle-Strand GK, et al. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009;15: 128-134.
12. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend. 2007;87:131-138. (Pubitemid 46215932)
13. Dryden C, Young D, Hepburn M, et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116:665-671.
14. Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12:109-124. (Pubitemid 351570866)
15. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668-681. (Pubitemid 44920225)
16. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16: 36-44. (Pubitemid 37532283)
17. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005;78:593-604. (Pubitemid 41773635)
18. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002;181-182:447-452. (Pubitemid 36015735)
19. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit. 2006;28:447-453. (Pubitemid 44314935)
20. Zhou HH, Sheller JR, Nu H, et al. Ethnic differences in response to morphine. Clin Pharmacol Ther. 1993;54:507-513. (Pubitemid 23349087)
21. Cepeda MS, Farrar JT, Roa JH, et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2001; 70:351-361. (Pubitemid 33022476)
22. Williams DG, Patel A, Howard RF. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth. 2002;89:839-845. (Pubitemid 35460521)
23. Ferreiros N, Dresen S, Hermanns-Clausen M, et al. Fatal and severe codeine intoxication in 3-year-old twins-interpretation of drug and metabolite concentrations. Int J Legal Med. 2009;123:387-394.
24. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827-2831. (Pubitemid 40051906)
25. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33. (Pubitemid 38130115)
26. Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008;84: 604-612.
27. Gray TR, Eiden RD, Leonard KE, et al. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem. 2010;56:1442-1450.
28. Montgomery D, Plate C, Alder SC, et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs. meconium. J Perinatol. 2006; 26:11-14. (Pubitemid 43135248)
29. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versusmethadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10. (Pubitemid 41557119)
30. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson NM, et al, eds. Primary Pediatric Care. St Louis, MO: Mosby-Year Book; 1992:1367-1378.
31. de Castro A, Concheiro M, Shakleya DM, et al. Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3065-3071.
32. de Castro A, Concheiro M, Shakleya DM, et al. Simultaneous quantification of methadone, cocaine, opiates, and metabolites in human placenta by liquid chromatography-mass spectrometry. J Anal Toxicol. 2009;33:243-252.
33. Choo RE, Murphy CM, Jones HE, et al. Determination of methadone, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine, 2-ethyl-5-methyl-3, 3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B, Analyt Technol Biomed Life Sci. 2005;814:369-373. (Pubitemid 40091657)
34. Gray TR, Shakleya DM, Huestis MA. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem. 2009; 393:1977-1990.
35. Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004;75:253-260. (Pubitemid 38993295)
36. Doberczak TM, Kandall SR, Friedmann P. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol. 1993;81:936.
37. Kuschel CA, Austerberry L, Cornwell M, et al. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal and Neonatal Ed. 2004;89: F390-F393. (Pubitemid 39178813)
38. Mack G, Thomas D, Giles W, et al. Methadone levels and neonatal withdrawal. J Paediatr Child Health. 1991;27:96-100.
39. Eap CB, Bourquin M, Martin JL, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend. 2000;61:47-54.
40. Harper RG, Solish G, Feingold E, et al. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol. 1977;129:417-424. (Pubitemid 8211784)
41. Kandall SR, Albin S, Gartner LM, et al. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev. 1977;1:159-169. (Pubitemid 8224194)
42. Finnegan LP. Management of pregnant drug-dependent women. Ann N Y Acad Sci. 1978;311:135-146.
43. Finnegan LP. Perinatal substance abuse: comments and perspectives. Semin Perinatol. 1991;15:331-339.
44. Rosen TS, Pippenger CE. Disposition of methadone and its relationship to severity of withdrawal in the newborn. Addict Dis. 1975;2:169-178.
45. Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr. 1976;88:1044-1048.
46. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, et al. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005; 69:187-197. (Pubitemid 39592885)
47. Blinick G, Inturrisi CE, Jerez E, et al. Methadone assays in pregnant women and progeny. Am J Obstet Gynecol. 1975;121:617-621.
48. Nikolaou PD, Papoutsis II, Atta-Politou J, et al. Validated method for the simultaneous determination of methadone and its main metabolites (EDDP and EMDP) in plasma of umbilical cord blood by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867:219-225.
49. Moore CM, Brown S, Negrusz A, et al. Determination of cocaine and its major metabolite, benzoylecgonine, in amniotic fluid, umbilical cord blood, umbilical cord tissue, and neonatal urine: a case study. J Anal Toxicol. 1993; 17:62. (Pubitemid 23030894)
50. Winecker RE, Goldberger BA, Tebbett I, et al. Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J Anal Toxicol. 1997;21:97-104. (Pubitemid 27131770)
51. Montgomery DP, Plate CA, Jones M, et al. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. J Perinatol. 2008;28:750-753.
52. Marin SJ, Christensen RD, Baer VL, et al. Nicotine and metabolites in paired umbilical cord tissue and meconium specimens. Ther Drug Monit. 2010;33:80-85.